ClinicalTrials.gg
RecruitingNCT07059754Updated May 26, 2026

A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP)

An interventional study of Topical Ophthalmic Cooling in Eye Pain, sponsored by EyeCool Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 22 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by EyeCool Therapeutics, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
22 Years to 90 Years
Sex
All
01

Study summary

The goal of this clinical trial is to understand what effect a cold treatment with an investigational device, ETX-4143, has on the anatomical structures and the inflammatory response of the surface of the eye in those people who suffer from chronic ocular surface pain (COSP). The trial will also tell us more about the safety of this investigational device. The main questions this study aims to answer are:

  • What anatomical changes happen to corneal surface nerves after treatment with ETX-4143
  • What changes in inflammatory mediators and cell response take place after treatment with ETX-4143

Researchers will obtain images of the corneal surface nerves for analysis using a confocal microscope and collect tear bio samples for analysis.

Participants will:

  • Be screened for having chronic ocular surface pain
  • Will be treated with ETX-4143 cold treatment for 4 minutes
  • Fill out a weekly questionnaire on eye pain for 12 weeks
  • Be seen in the clinic 2 weeks, 6 weeks, and 12 weeks after treatment to have images of the corneal surface taken, and to collect a tear bio sample
Read the detailed description

EyeCool Therapeutics was founded on the hypothesis that a mild ocular surface cooling treatment, delivered through its proprietary cooling device (ETX-4143), can improve the symptoms of chronic ocular surface pain by transiently inhibiting nerve signaling, and potentially reducing ocular surface inflammation, and potentially restoring normal ocular surface nerve function.

The ETX-4143 Device is a handheld medical device that contains an internal frozen (-20° Centigrade) mixture of purified water and glycerol. The ETX-4143 Device does not contain an active pharmaceutical ingredient. The frozen mixture internally cools two metallic probes that contact the conjunctival surface of the patient; there is no direct contact of the ocular surface with the frozen mixture. Prior to placement of the device on the ocular surface, local anesthesia is administered and a custom speculum used to open and insulate the eyelids, as well as promote correct positioning of the Device. A cornea shield is applied to maintain corneal wetness during the procedure. The Device and accessory (speculum) are provided in disposable, single-use packaging.

In this prospective, single-center, single-center clinical study, 5 adult subjects with chronic ocular surface pain will be identified and treated with the ETX-4143 Device (Cooling Device for topical ophthalmic use). The main goal of the study is to further evaluate the device for changes in ocular surface components using in vivo confocal microscopy, and for safety and efficacy. Improvement in self-reported ocular discomfort and clinical safety measures will be evaluated, along with in vivo confocal microscopy of the cornea before and after treatment.

It is anticipated that the learnings from these observations will be used to design future studies of the ETX-4143 device. In this study, five subjects will receive the investigational product (ETX-4143 Device).

The Medical Monitor will evaluate the clinical safety data as it becomes available and no less than on at least a quarterly basis.

All subjects will be followed for a total of 12 weeks. Subjects will have only the worse eye treated, if both eyes meet the inclusion/exclusion criteria. The worse eye will be determined by the investigator based on subjective reporting from the study subject of chronic ocular surface pain and/or other screening assessments in each eye. Both eyes will be assessed for tear osmolarity and imaged using corneal in vivo confocal microscopy at the University of Melbourne, with the untreated eye representing a control.

02

Conditions studied

  • Eye Pain

Browse trials for

Keywords

  • Chronic Ocular Surface Pain
  • Ophthalmic Cooling
  • Topical Ophthalmic Cooling
  • Cooling Device
  • Ocular Surface
03

In context

Eye Pain

31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.

This study's planned enrollment of 5 is below the median of 55 across 28 interventional studies indexed under Eye Pain.

Browse Eye Pain studies →

Lead sponsor

EyeCool Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented symptoms of COSP pain for at least 3 months
  • A score of ≥5 on the single question COP-Q Eye Pain Severity Module
  • Able to obtain sufficient quality corneal in-vivo confocal microscopy images

Exclusion criteria

Exclusion Criteria:

  • Less than 50% improvement in VAS Eye Pain score after topical 0.5% proparacaine hydrochloride at screening
  • Subjects with corneal scarring that could limit the confocal microscopy
  • Insufficient number of corneal nerves to permit Fun-IVCM imaging
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Interventional

    Eyes that are treated with the ETX-4143 topical ophthalmic cooling device

    Device: Topical Ophthalmic Cooling

Interventions

  • DeviceTopical Ophthalmic Cooling

    Targeted topical ophthalmic cooling treatment using the ETX-4143 cooling device

06

What researchers measure

Primary outcomes

  1. Corneal Confocal In-vivo Microscopy Image Analysis

    Non-invasive imaging of the corneal surface for assessing ocular tissue structure.

    Time frame: From treatment to the end of twelve weeks

07

Study locations

1 of 1 sites recruiting
  • Sunshine Eye Surgeons
    Melbourne, Victoria 3021, Australia
    Recruiting
    • Rachel McIntosh Managing Director, MPH · Contactrlm@zave.com.au · +61 0402 133 315
08

References and documents

Publications

  • Galor A, Hamrah P, Haque S, Attal N, Labetoulle M. Understanding chronic ocular surface pain: An unmet need for targeted drug therapy. Ocul Surf. 2022 Oct;26:148-156. doi: 10.1016/j.jtos.2022.08.005. Epub 2022 Aug 13. PubMed 35970433 ↗
  • Chiang JCB, Wu M, Lee JH, Curkpatrick A, Ifantides C, Nguyen T, Galor A, Wu H, Lindstrom R, Thompson V, Downie LE. Impact of an Ophthalmic Cooling Device on Corneal Immune and Sensory Nerve Features in Chronic Ocular Surface Pain: A Prospective, Feasibility Study. Ophthalmol Ther. 2026 Jul 15. doi: 10.1007/s40123-026-01454-6. Online ahead of print. PubMed 42455250 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2025
First posted
Jul 11, 2025
StartActual
Aug 25, 2025
Primary completionEst.
Jul 15, 2026
CompletionEst.
Jul 15, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059754
Lead sponsor
EyeCool Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Aug 25, 2025
Primary completion
Jul 15, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
May 26, 2026

Study contacts

Patrick Casey, Optometrist
Contact
patrick.casey@eyecooltx.com
15104100543
Cristos Ifantides A Prospective, Feasibility, Single-Center, Clinical Study to E
Contact
cristos.ifantides@eyecooltx.com
Patrick Casey R VP of Clinical Development, Optometrist
study chair · EyeCool Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion